Table 2. Ongoing clinical trials in idiopathic pulmonary fibrosis
Trial#DrugMechanism of action
ASCEND (NCT01366209)PirfenidoneAntifibrotic
NCT01335477BIBF 1120Tyrosine-kinase inhibitor
NCT01335464BIBF 1120Tyrosine-kinase inhibitor
NCT01266135QAX576Anti-IL-13 monoclonal antibody
NCT00786201CNTO 888Anti-CCL-2 monoclonal antibody
NCT01262001FG-3019Anti-CTGF antibody
NCT01362231AB0024Anti-LOXL2 monoclonal antibody
NCT01385644MSCsEpithelial tissue repair

  • MSC: mesenchymal stem cell; IL: interleukin; CCL: chemokine (C–C motif) ligand; CTGF: connective tissue growth factor; LOXL: lysyl oxidase-like. #: identifier numbers are provided for http://clinicaltrials.gov/